FLAG-Ida regimen as bridge therapy to allotransplant in refractory/relapsed AML patients

Publication date: Available online 19 June 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Mario Delia, Domenico Pastore, Paola Carluccio, Crescenza Pasciolla, Alessandra Ricco, Antonella Russo Rossi, Paola Casieri, Anna Mestice, Francesco Albano, Giorgina Specchia Primary refractory/first relapse AML patients are considered to have a worse clinical outcome post-treatment. For these patients the achievement of CR appears to be crucial in order to be able to undergo allotransplantation, maybe the only possible treatment. We used the FLAG-Ida regimen in this kind of patients as a bridge to transplant, and studied its efficacy in terms of overall response (OR) and survival (OS) rates, to assess which variables (age, LDH, bone marrow (BM), peripheral blood (PB) blasts and platelets counts, white blood cells (WBC), de novo or secondary AML, molecular-cytogentic risk, duration of response and relapsed or refractory disease), might have an impact on the outcome. We analyzed 108 consecutive adult patients (52 males, 66 females; median age 49 years, range 17-72) with newly diagnosed acute myeloid leukemia refractory to standard induction regimens or relapsed after 1stCR, who received the FLAG-Ida protocol as salvage therapy between January 2005 and December 2015. OR was achieved in 48 patients (44%) and, on multivariate analysis, variables with a positive impact on response rate were molecular-cytogenetic risk (p=0.009), duration of 1st response in relapsed A...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research